

# François Marceau

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7990701/publications.pdf>

Version: 2024-02-01

192  
papers

7,472  
citations

93792

39  
h-index

71088

80  
g-index

198  
all docs

198  
docs citations

198  
times ranked

5572  
citing authors

#	ARTICLE	IF	CITATIONS
1	In vitro pharmacological profile of PHA-022121, a small molecule bradykinin B2 receptor antagonist in clinical development. <i>International Immunopharmacology</i> , 2022, 105, 108523.	1.7	8
2	Picomolar Sensitivity Analysis of Multiple Bradykinin-Related Peptides in the Blood Plasma of Patients With Hereditary Angioedema in Remission: A Pilot Study. <i>Frontiers in Allergy</i> , 2022, 3, 837463.	1.2	3
3	C5a receptor antagonism coming of age for vascular pathology. <i>International Immunopharmacology</i> , 2022, 110, 109042.	1.7	3
4	Are noscapine and raloxifene ligands of the bradykinin B2 receptor? An assessment based on the human umbilical vein contractility assay. <i>International Immunopharmacology</i> , 2022, 110, 108984.	1.7	0
5	A Robust Bioassay of the Human Bradykinin B2 Receptor That Extends Molecular and Cellular Studies: The Isolated Umbilical Vein. <i>Pharmaceuticals</i> , 2021, 14, 177.	1.7	2
6	Covid-19 challenges to immune investigations and therapies. <i>International Immunopharmacology</i> , 2021, 95, 107543.	1.7	1
7	Bradykinin receptors in GtoPdb v.2021.3. <i>IUPHAR/BPS Guide To Pharmacology CITE</i> , 2021, 2021, .	0.2	0
8	In Vitro Modeling of Bradykinin-Mediated Angioedema States. <i>Pharmaceuticals</i> , 2020, 13, 201.	1.7	5
9	The development of a targeted and more potent, anti-inflammatory derivative of colchicine: Implications for gout. <i>Biochemical Pharmacology</i> , 2020, 180, 114125.	2.0	10
10	In Vitro Pharmacological Profile of a New Small Molecule Bradykinin B2 Receptor Antagonist. <i>Frontiers in Pharmacology</i> , 2020, 11, 916.	1.6	10
11	Measurement of Bradykinin Formation and Degradation in Blood Plasma: Relevance for Acquired Angioedema Associated With Angiotensin Converting Enzyme Inhibition and for Hereditary Angioedema Due to Factor XII or Plasminogen Gene Variants. <i>Frontiers in Medicine</i> , 2020, 7, 358.	1.2	17
12	Bradykinin receptors: Agonists, antagonists, expression, signaling, and adaptation to sustained stimulation. <i>International Immunopharmacology</i> , 2020, 82, 106305.	1.7	73
13	Increased fibrinolysis-induced bradykinin formation in hereditary angioedema confirmed using stored plasma and biotechnological inhibitors. <i>BMC Research Notes</i> , 2019, 12, 291.	0.6	14
14	Bradykinin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. <i>IUPHAR/BPS Guide To Pharmacology CITE</i> , 2019, 2019, .	0.2	1
15	Bifunctional fusion proteins containing the sequence of the bradykinin homologue maximakinin: activities at the rat bradykinin B2 receptor. <i>Canadian Journal of Physiology and Pharmacology</i> , 2018, 96, 459-470.	0.7	2
16	Editorial: Correspondence from Chirumbolo and Bjorklund. <i>International Immunopharmacology</i> , 2018, 55, A1.	1.7	0
17	Comparing Pathways of Bradykinin Formation in Whole Blood From Healthy Volunteers and Patients With Hereditary Angioedema Due to C1 Inhibitor Deficiency. <i>Frontiers in Immunology</i> , 2018, 9, 2183.	2.2	13
18	Bifunctional ligands of the bradykinin B 2 and B 1 receptors: An exercise in peptide hormone plasticity. <i>Peptides</i> , 2018, 105, 37-50.	1.2	17

#	ARTICLE	IF	CITATIONS
19	D-Arg0-Bradykinin-Arg-Arg, a Latent Vasoactive Bradykinin B2 Receptor Agonist Metabolically Activated by Carboxypeptidases. <i>Frontiers in Pharmacology</i> , 2018, 9, 273.	1.6	7
20	Reprint of: Editorial: Correspondence from Chirumbolo and Bjorklund. <i>International Immunopharmacology</i> , 2018, 62, 334.	1.7	0
21	Latent Bradykinin B 2 Receptor Agonist: Differential Vascular and Hemodynamic Effects Dependent On The Effector Carboxypeptidases. <i>FASEB Journal</i> , 2018, 32, .	0.2	0
22	S100A9 potentiates the activation of neutrophils by the etiological agent of gout, monosodium urate crystals. <i>Journal of Leukocyte Biology</i> , 2017, 102, 805-813.	1.5	15
23	Production and evaluation of parathyroid hormone receptor1 ligands with intrinsic or assembled peroxidase domains. <i>Scientific Reports</i> , 2017, 7, 13099.	1.6	3
24	Species-specific pharmacology of maximakinin, an amphibian homologue of bradykinin: putative prodrug activity at the human B <sub>2</sub> receptor and peptidase resistance in rats. <i>PeerJ</i> , 2017, 5, e2911.	0.9	6
25	Infrared-emitting, peptidase-resistant fluorescent ligands of the bradykinin B2 receptor: application to cytofluorometry and imaging. <i>BMC Research Notes</i> , 2016, 9, 452.	0.6	8
26	The isolated human umbilical vein as a bioassay for kinin-generating proteases: An in vitro model for therapeutic angioedema agents. <i>Life Sciences</i> , 2016, 155, 180-188.	2.0	6
27	Editorial: Improving the data reproducibility and general interest of natural product submissions. <i>International Immunopharmacology</i> , 2016, 37, 3-4.	1.7	2
28	Lysosomotropic cationic drugs induce cytostatic and cytotoxic effects: Role of liposolubility and autophagic flux and antagonism by cholesterol ablation. <i>Toxicology and Applied Pharmacology</i> , 2016, 305, 55-65.	1.3	15
29	Introduction: Natural product-based drug discovery in Immunopharmacology. <i>International Immunopharmacology</i> , 2016, 37, 1-2.	1.7	3
30	Biotechnological Fluorescent Ligands of the Bradykinin B1 Receptor: Protein Ligands for a Peptide Receptor. <i>PLoS ONE</i> , 2016, 11, e0148246.	1.1	6
31	Pharmacological effects of recombinant human tissue kallikrein on bradykinin B <sub>2</sub> receptors. <i>Pharmacology Research and Perspectives</i> , 2015, 3, e00119.	1.1	15
32	Pharmacological profile of a bifunctional ligand of the formyl peptide receptor1 fused to the myc epitope. <i>International Immunopharmacology</i> , 2015, 25, 229-234.	1.7	0
33	In Vivo Effects of Bradykinin B2 Receptor Agonists with Varying Susceptibility to Peptidases. <i>Frontiers in Pharmacology</i> , 2015, 6, 306.	1.6	9
34	Autophagic flux inhibition and lysosomogenesis ensuing cellular capture and retention of the cationic drug quinacrine in murine models. <i>PeerJ</i> , 2015, 3, e1314.	0.9	18
35	Pharmacological evidence of bradykinin regeneration from extended sequences that behave as peptidase-activated B2 receptor agonists. <i>Frontiers in Pharmacology</i> , 2014, 5, 32.	1.6	8
36	Assessment of Cation Trapping by Cellular Acidic Compartments. <i>Methods in Enzymology</i> , 2014, 534, 119-131.	0.4	8

#	ARTICLE	IF	CITATIONS
37	A tagged parathyroid hormone derivative as a carrier of antibody cargoes transported by the G protein coupled PTH1 receptor. <i>Peptides</i> , 2014, 60, 71-79.	1.2	5
38	Vasopeptidase-activated latent ligands of the histamine receptor-1. <i>International Immunopharmacology</i> , 2013, 17, 677-683.	1.7	7
39	Inhibitory effects of cytoskeleton disrupting drugs and GDP-locked Rab mutants on bradykinin B2 receptor cycling. <i>Pharmacological Research</i> , 2013, 71, 44-52.	3.1	12
40	Green fluorescent protein fused to peptide agonists of two dissimilar G protein-coupled receptors: novel ligands of the bradykinin B <sub>2</sub> (rhodopsin family) receptor and parathyroid hormone <sc>PTH</sc> (secretin family) receptor. <i>Pharmacology Research and Perspectives</i> , 2013, 1, e00004.	1.1	15
41	High affinity capture and concentration of quinacrine in polymorphonuclear neutrophils via vacuolar ATPase-mediated ion trapping: Comparison with other peripheral blood leukocytes and implications for the distribution of cationic drugs. <i>Toxicology and Applied Pharmacology</i> , 2013, 270, 77-86.	1.3	8
42	NLRP3 promotes autophagy of urate crystals phagocytized by human osteoblasts. <i>Arthritis Research and Therapy</i> , 2013, 15, R176.	1.6	38
43	Bifunctional epitope-agonist ligands of the bradykinin B <sub>2</sub> receptor. <i>Biological Chemistry</i> , 2013, 394, 379-383.	1.2	6
44	C-C chemokine receptor-7 mediated endocytosis of antibody cargoes into intact cells. <i>Frontiers in Pharmacology</i> , 2013, 4, 122.	1.6	10
45	Characterization of recombinant traceable analogs of the parathyroid hormone. <i>FASEB Journal</i> , 2013, 27, 1170.1.	0.2	0
46	N-terminal extended conjugates of the agonists and antagonists of both bradykinin receptor subtypes: Structure-activity relationship, cell imaging using ligands conjugated with fluorophores and prospect for functionally active cargoes. <i>Peptides</i> , 2012, 34, 433-446.	1.2	16
47	Prolonged signalling and trafficking of the bradykinin B2 receptor stimulated with the amphibian peptide maximakinin: Insight into the endosomal inactivation of kinins. <i>Pharmacological Research</i> , 2012, 65, 247-253.	3.1	18
48	Cation trapping by cellular acidic compartments: Beyond the concept of lysosomotropic drugs. <i>Toxicology and Applied Pharmacology</i> , 2012, 259, 1-12.	1.3	99
49	An in vitro reconstitution system to address the mechanism of the vascular expression of the bradykinin B1 receptor in response to angiotensin converting enzyme inhibition. <i>Vascular Pharmacology</i> , 2012, 57, 15-23.	1.0	3
50	Dissociation of the vacuolar and macroautophagic cytopathology from the cytotoxicity induced by the lipophilic local anesthetic bupivacaine. <i>Canadian Journal of Physiology and Pharmacology</i> , 2011, 89, 505-512.	0.7	6
51	Met-Lys-bradykinin-Ser-Ser, a peptide produced by the neutrophil from kininogen, is metabolically activated by angiotensin converting enzyme in vascular tissue. <i>Pharmacological Research</i> , 2011, 64, 528-534.	3.1	12
52	Bradykinin B2 receptor-mediated transport into intact cells: Anti-receptor antibody-based cargoes. <i>European Journal of Pharmacology</i> , 2011, 668, 107-114.	1.7	12
53	Design of Fluorescent Bradykinin Analogs: Application to Imaging of B <sub>2</sub> Receptor-Mediated Agonist Endocytosis and Trafficking and Angiotensin-Converting Enzyme. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 337, 33-41.	1.3	19
54	5 Drugs in the kallikrein-kinin system. , 2011, , .		3

#	ARTICLE	IF	CITATIONS
55	Angiotensin converting enzyme inhibitor induced angioedema: a review of the pathophysiology and risk factors. <i>Clinical and Experimental Allergy</i> , 2010, 40, 50-61.	1.4	96
56	Vacuolar ATPase-mediated sequestration of local anesthetics in swollen macroautophagosomes. <i>Canadian Journal of Anaesthesia</i> , 2010, 57, 230-239.	0.7	20
57	Guest Editorial for the Special Issue Peptide Receptors: Focus on Neuropeptides and Kinins. <i>Neuropeptides</i> , 2010, 44, 65-67.	0.9	0
58	Altered cardiac bradykinin metabolism in experimental diabetes caused by the variations of angiotensin-converting enzyme and other peptidases. <i>Neuropeptides</i> , 2010, 44, 69-75.	0.9	9
59	Effect of interferon- $\beta$ on inflammatory cytokine-induced bradykinin B1 receptor expression in human vascular cells. <i>European Journal of Pharmacology</i> , 2010, 647, 117-125.	1.7	27
60	Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro. <i>Biomaterials</i> , 2010, 31, 5741-5748.	5.7	31
61	NTPDase1 (CD39) controls nucleotide-dependent vasoconstriction in mouse. <i>Cardiovascular Research</i> , 2010, 85, 204-213.	1.8	88
62	Vascular smooth muscle contractility assays for inflammatory and immunological mediators. <i>International Immunopharmacology</i> , 2010, 10, 1344-1353.	1.7	17
63	A ligand-based approach to investigate the expression and function of angiotensin converting enzyme in intact human umbilical vein endothelial cells. <i>Peptides</i> , 2010, 31, 1546-1554.	1.2	16
64	Fluorescent Ligands of the Bradykinin B1 Receptors: Pharmacologic Characterization and Application to the Study of Agonist-Induced Receptor Translocation and Cell Surface Receptor Expression. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 329, 159-168.	1.3	18
65	Vacuolar ATPase-Mediated Cellular Concentration and Retention of Quinacrine: A Model for the Distribution of Lipophilic Cationic Drugs to Autophagic Vacuoles. <i>Drug Metabolism and Disposition</i> , 2009, 37, 2271-2274.	1.7	30
66	Receptor tyrosine kinases as mediators of injury-induced bradykinin B1 receptor expression in rabbit aortic smooth muscle. <i>European Journal of Pharmacology</i> , 2009, 606, 233-239.	1.7	5
67	Intracellular sequestration of amiodarone: role of vacuolar ATPase and macroautophagic transition of the resulting vacuolar cytopathology. <i>British Journal of Pharmacology</i> , 2009, 157, 1531-1540.	2.7	58
68	Effects of inactivation-resistant agonists on the signalling, desensitization and downregulation of bradykinin B <sub>2</sub> receptors. <i>British Journal of Pharmacology</i> , 2009, 158, 1375-1386.	2.7	29
69	Tumor cells expressing tissue factor influence the migration of smooth muscle cells in a catalytic activity-dependent way. <i>Canadian Journal of Physiology and Pharmacology</i> , 2009, 87, 694-701.	0.7	8
70	Therapeutic options in inflammatory bowel disease: experimental evidence of a beneficial effect of kinin B <sub>1</sub> receptor blockade. <i>British Journal of Pharmacology</i> , 2008, 154, 1163-1165.	2.7	15
71	Intense pseudotransport of a cationic drug mediated by vacuolar ATPase: Procainamide-induced autophagic cell vacuolization. <i>Toxicology and Applied Pharmacology</i> , 2008, 228, 364-377.	1.3	39
72	Receptor-independent, vacuolar ATPase-mediated cellular uptake of histamine receptor-1 ligands: Possible origin of pharmacological distortions and side effects. <i>Toxicology and Applied Pharmacology</i> , 2008, 229, 320-331.	1.3	17

#	ARTICLE	IF	CITATIONS
73	Structural modification of the highly potent peptide bradykinin B1 receptor antagonist B9958. <i>International Immunopharmacology</i> , 2008, 8, 289-292.	1.7	23
74	Cardiovascular expression of inflammatory signaling molecules, the kinin B1 receptor and COX2, in the rabbit: Effects of LPS, anti-inflammatory and anti-hypertensive drugs. <i>Regulatory Peptides</i> , 2008, 146, 157-168.	1.9	10
75	Lack of direct interaction between enalaprilat and the kinin B1 receptors. <i>Peptides</i> , 2008, 29, 606-612.	1.2	22
76	A fluorescent version of the bradykinin B2 receptor antagonist B-9430: Pharmacological characterization and use in live cell imaging. <i>Peptides</i> , 2008, 29, 1626-1630.	1.2	13
77	Role of Nuclear Factor- $\kappa$ B and Protein Kinase C Signaling in the Expression of the Kinin B1 Receptor in Human Vascular Smooth Muscle Cells. <i>Molecular Pharmacology</i> , 2007, 71, 949-956.	1.0	37
78	B-9972 (D-Arg-[Hyp3,Igl5,Oic7,Igl8]-bradykinin) Is an Inactivation-Resistant Agonist of the Bradykinin B2 Receptor Derived from the Peptide Antagonist B-9430 (D-Arg-[Hyp3,Igl5,D-Igl7,Oic8]-bradykinin): Pharmacologic Profile and Effective Induction of Receptor Degradation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 323, 534-546.	1.3	32
79	Does zaltoprofen antagonize the bradykinin receptors?. <i>Regulatory Peptides</i> , 2007, 140, 125-130.	1.9	6
80	Trapping of adrenergic decongestant drugs into cellular endomembrane compartments: Toxicological and pharmacological consequences. <i>International Immunopharmacology</i> , 2007, 7, 1869-1879.	1.7	9
81	B-2 Bradykinin Receptor. , 2007, , 1-14.		1
82	Antagonist, partial agonist and antiproliferative actions of B-9870 (CU201) as a function of the expression and density of the bradykinin B1 and B2 receptors. <i>British Journal of Pharmacology</i> , 2007, 150, 369-379.	2.7	27
83	The antiwrinkle effect of topical concentrated 2-dimethylaminoethanol involves a vacuolar cytopathology. <i>British Journal of Dermatology</i> , 2007, 156, 433-439.	1.4	23
84	Generation of kinins during preparation and storage of whole blood-derived platelet concentrates. <i>Transfusion</i> , 2007, 47, 410-420.	0.8	22
85	Pseudotransport of cationic drugs into human smooth muscle cells: comparison of vacuolar (V)-ATPase-driven ion trapping with other forms of cellular uptake. <i>FASEB Journal</i> , 2007, 21, A1188.	0.2	0
86	Bradykinin Receptors. , 2007, , 1-4.		0
87	B-1 Bradykinin Receptor. , 2007, , 1-12.		0
88	Characterization of B-9972, a peptidase-resistant agonist of the bradykinin B2 receptors: effects on the endocytosis and recycling of the receptors. <i>FASEB Journal</i> , 2007, 21, A433.	0.2	0
89	The bradykinin B2 receptor antagonist icatibant (Hoe 140) blocks aminopeptidase N at micromolar concentrations: Off-target alterations of signaling mediated by the bradykinin B1 and angiotensin receptors. <i>European Journal of Pharmacology</i> , 2006, 551, 108-111.	1.7	9
90	Discovery of a Dual-Function Peptide That Combines Aminopeptidase N Inhibition and Kinin B1 Receptor Antagonism. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 317, 300-308.	1.3	14

#	ARTICLE	IF	CITATIONS
91	Molecular identification and pharmacological profile of the bovine kinin B1 receptor. <i>Biological Chemistry</i> , 2006, 387, 211-215.	1.2	2
92	Dual antagonists of the bradykinin B1 and B2 receptors based on a postulated common pharmacophore from existing non-peptide antagonists. <i>Biological Chemistry</i> , 2006, 387, 189-94.	1.2	5
93	Inhibition of human and rabbit arterial smooth muscle cell migration mediated by the kinin B1 receptor: role of receptor density and released mediators. <i>Canadian Journal of Physiology and Pharmacology</i> , 2006, 84, 1107-1119.	0.7	17
94	A Nonpeptide Antagonist Reveals a Highly Glycosylated State of the Rabbit Kinin B1 Receptor. <i>Molecular Pharmacology</i> , 2006, 69, 1146-1157.	1.0	32
95	Advances in the Development of Bradykinin Receptor Ligands. <i>Current Topics in Medicinal Chemistry</i> , 2006, 6, 1353-1363.	1.0	18
96	The Kallikrein-Kinin System: Current and Future Pharmacological Targets. <i>Journal of Pharmacological Sciences</i> , 2005, 99, 6-38.	1.1	400
97	Studies on rabbit natural and recombinant tissue factors: intracellular retention and regulation of surface expression in cultured cells. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2005, 288, H2192-H2202.	1.5	10
98	International Union of Pharmacology. XLV. Classification of the Kinin Receptor Family: from Molecular Mechanisms to Pathophysiological Consequences. <i>Pharmacological Reviews</i> , 2005, 57, 27-77.	7.1	869
99	Expression of Metallopeptidases and Kinin Receptors in Swine Oropharyngeal Tissues: Effects of Angiotensin I-Converting Enzyme Inhibition and Inflammation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 315, 1065-1074.	1.3	24
100	N-Substituted 4-Aminobenzamides (Procainamide Analogs): An Assessment of Multiple Cellular Effects Concerning Ion Trapping. <i>Molecular Pharmacology</i> , 2005, 68, 1576-1589.	1.0	19
101	Endogenous Aminopeptidase N Decreases the Potency of Peptide Agonists and Antagonists of the Kinin B1 Receptors in the Rabbit Aorta. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 314, 1169-1176.	1.3	22
102	A possible common pharmacophore in the non-peptide antagonists of the bradykinin B1 receptor. <i>Trends in Pharmacological Sciences</i> , 2005, 26, 116-118.	4.0	8
103	Massive Cell Vacuolization Induced by Organic Amines Such as Procainamide. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 310, 395-406.	1.3	62
104	A Novel Nonpeptide Antagonist of the Kinin B1 Receptor: Effects at the Rabbit Receptor. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 311, 1121-1130.	1.3	26
105	Bradykinin receptor ligands: therapeutic perspectives. <i>Nature Reviews Drug Discovery</i> , 2004, 3, 845-852.	21.5	326
106	Loss of function of vascular smooth muscle cells by nitric oxide-dependent and -independent interactions with tumorigenic cells. <i>International Journal of Cancer</i> , 2004, 112, 830-839.	2.3	10
107	Characterization of a fluorescent conjugate of the rabbit angiotensin AT1 receptor. <i>British Journal of Pharmacology</i> , 2003, 138, 1495-1504.	2.7	5
108	A non-peptide antagonist unusually selective for the human form of the bradykinin B2 receptor. <i>International Immunopharmacology</i> , 2003, 3, 1529-1536.	1.7	12

#	ARTICLE	IF	CITATIONS
109	Tissue Kallikrein Actions at the Rabbit Natural or Recombinant Kinin B2Receptors. Hypertension, 2003, 41, 611-617.	1.3	25
110	Do angiotensin-converting enzyme inhibitors directly stimulate the kinin B1 receptor?. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 285, H277-H282.	1.5	23
111	Wortmannin alters the intracellular trafficking of the bradykinin B2 receptor: role of phosphoinositide 3-kinase and Rab5. Biochemical Journal, 2003, 375, 151-158.	1.7	29
112	High agonist-independent clearance of rabbit kinin B1 receptors in cultured cells. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 284, H1647-H1654.	1.5	15
113	Agonist-Induced Translocation of the Kinin B1Receptor to Caveolae-Related Rafts. Molecular Pharmacology, 2002, 61, 546-553.	1.0	97
114	Contractile Effect of Anaphylatoxin C5a and of a Mimetic Peptide on the Human Umbilical Artery: Further Evidence for Leukocyte-Dependent Vasomotion. Journal of Cardiovascular Pharmacology, 2002, 40, 815-821.	0.8	7
115	Bradykinin B2receptor gene polymorphism is associated with altered urinary albumin/creatinine values in diabetic patients. Canadian Journal of Physiology and Pharmacology, 2002, 80, 323-327.	0.7	33
116	Kinin receptors: functional aspects. International Immunopharmacology, 2002, 2, 1729-1739.	1.7	59
117	Expression of kinin B1 receptor in fresh or cultured rabbit aortic smooth muscle: role of NF- $\kappa$ B. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 283, H227-H237.	1.5	37
118	Effects of two novel non-peptide antagonists at the rabbit bradykinin B2 receptor. Peptides, 2001, 22, 1397-1402.	1.2	10
119	Absence of ligand-induced regulation of kinin receptor expression in the rabbit. British Journal of Pharmacology, 2001, 133, 1154-1162.	2.7	18
120	Ligand-Mediated Regulation of Kinin Receptors in the Rabbit. Biological Chemistry, 2001, 382, 131-3.	1.2	4
121	The contribution of angiotensin-converting enzyme (ACE) to the metabolism of kinins (bradykinin and) Tj ETQq1 1 0.784314 rgBT /Ov 1 129-144.	1.0	1
122	In vivo protein-DNA interactions at the kinin B1 receptor gene promoter: No modification on interleukin-1 beta or lipopolysaccharide induction. Journal of Cellular Biochemistry, 2000, 78, 278-296.	1.2	26
123	Non-competitive pharmacological antagonism at the rabbit B1 receptor. British Journal of Pharmacology, 2000, 131, 885-892.	2.7	27
124	Inflammatory hyperalgesia induced by zymosan in the plantar tissue of the rat: effect of kinin receptor antagonists. Immunopharmacology, 2000, 46, 139-147.	2.0	41
125	p38 MAP kinase pathway regulates angiotensin II-induced contraction of rat vascular smooth muscle. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 279, H741-H751.	1.5	96
126	Antagonist-Induced Intracellular Sequestration of Rabbit Bradykinin B <sub>2</sub> Receptor. Hypertension, 2000, 35, 1319-1325.	1.3	56

#	ARTICLE	IF	CITATIONS
127	The kallikrein-kininogen-kinin system: lessons from the quantification of endogenous kinins. <i>Peptides</i> , 2000, 21, 1903-1940.	1.2	119
128	Altered frequency of a promoter polymorphism of the kinin B2 receptor gene in hypertensive African-Americans. <i>American Journal of Hypertension</i> , 2000, 13, 1268-1273.	1.0	53
129	Effect of endogenous kinins, prostanoids, and NO on kinin B1 and B2 receptor expression in the rabbit. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 1999, 277, R1568-R1578.	0.9	18
130	Cloning and preliminary pharmacological characterization of the anaphylatoxin C5a receptor in the rabbit. <i>British Journal of Pharmacology</i> , 1999, 128, 321-326.	2.7	12
131	Characterization of a polymorphism in the coding region of the human C5a anaphylatoxin receptor. <i>Immunogenetics</i> , 1999, 49, 618-619.	1.2	5
132	Kinin receptors. <i>Clinical Reviews in Allergy and Immunology</i> , 1998, 16, 385-401.	2.9	130
133	Down-regulation of interleukin-1 $\beta$ production and PGE2 accumulation by an indomethacin-phenylalanine derivative in human monocytes. <i>Life Sciences</i> , 1998, 62, 2241-2247.	2.0	7
134	Altered frequency of a promoter polymorphic allele of the kinin B receptor gene in inflammatory bowel disease. <i>Gastroenterology</i> , 1998, 115, 1045-1048.	0.6	36
135	Interleukin 8 (IL-8) Induces the Expression of Kinin B1Receptor in Human Lung Fibroblasts. <i>Biochemical and Biophysical Research Communications</i> , 1998, 253, 750-755.	1.0	16
136	Characterization of two polymorphic sites in the human kinin B1 receptor gene. <i>Journal of the American Society of Nephrology: JASN</i> , 1998, 9, 598-604.	3.0	43
137	Human kallikrein hK2 has low kininogenase activity while prostate-specific antigen (hK3) has none. <i>BBA - Proteins and Proteomics</i> , 1997, 1343, 102-106.	2.1	31
138	Kinin B1 Receptor Induction and Inflammation. , 1997, , 143-156.		14
139	The kinin B <sub>1</sub> receptor: an inducible G protein coupled receptor. <i>Canadian Journal of Physiology and Pharmacology</i> , 1997, 75, 725-730.	0.7	32
140	Oxidative Stress-Induced Actin Reorganization Mediated by the p38 Mitogen-Activated Protein Kinase/Heat Shock Protein 27 Pathway in Vascular Endothelial Cells. <i>Circulation Research</i> , 1997, 80, 383-392.	2.0	516
141	Structure and Genomic Organization of the Human B1Receptor Gene for Kinins (BDKRB1). <i>Genomics</i> , 1996, 33, 374-381.	1.3	56
142	Evidence for vascular tone regulation by resident or infiltrating leukocytes. <i>Biochemical Pharmacology</i> , 1996, 52, 1481-1488.	2.0	10
143	Inflammatory Peptides at the Beginning of Hemodialysis in Asymptomatic Patients Treated or Not with Angiotensin I-Converting Inhibitors. <i>Nephron</i> , 1995, 71, 474-476.	0.9	5
144	Development of a binding assay for the B1 receptors for kinins. <i>Immunopharmacology</i> , 1995, 29, 141-147.	2.0	36

#	ARTICLE	IF	CITATIONS
145	Kinin B1 receptors: a review. <i>Immunopharmacology</i> , 1995, 30, 1-26.	2.0	378
146	Recombinant Human Hemoglobin (rHb1.1) Selectively Inhibits Vasorelaxation Elicited by Nitric Oxide Donors in Rabbit Isolated Aortic Rings. <i>Journal of Cardiovascular Pharmacology</i> , 1995, 25, 587-594.	0.8	50
147	Mode of action of thrombin in the rabbit aorta. <i>British Journal of Pharmacology</i> , 1995, 115, 903-908.	2.7	24
148	Regulation of kinin-induced contraction and DNA synthesis by inflammatory cytokines in the smooth muscle of the rabbit aorta. <i>British Journal of Pharmacology</i> , 1995, 116, 1673-1679.	2.7	31
149	Quantification of des-Arg <sup>9</sup> -bradykinin using a chemiluminescence enzyme immunoassay: application to its kinetic profile during plasma activation. <i>Journal of Immunological Methods</i> , 1995, 180, 247-257.	0.6	62
150	Recombinant Human Hemoglobin Inhibits Both Constitutive and Cytokine-Induced Nitric Oxide-Mediated Relaxation of Rabbit Isolated Aortic Rings. <i>Journal of Cardiovascular Pharmacology</i> , 1994, 24, 229-237.	0.8	46
151	Epidermal growth factor-induced rapid relaxation of the isolated rabbit mesenteric artery. <i>European Journal of Pharmacology</i> , 1994, 259, 91-94.	1.7	6
152	Aminopeptidase modulation of the pharmacological responses to synthetic thrombin receptor agonists. <i>European Journal of Pharmacology</i> , 1994, 253, 225-230.	1.7	13
153	Further analysis of the upregulation of bradykinin B1 receptors in isolated rabbit aorta by using metabolic inhibitors. <i>European Journal of Pharmacology</i> , 1994, 271, 551-555.	1.7	35
154	The nonpeptide WIN 64338 is a bradykinin B2 receptor antagonist.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1994, 91, 4693-4697.	3.3	75
155	Synthetic C5a receptor agonists. <i>Biochemical Pharmacology</i> , 1993, 45, 1289-1299.	2.0	32
156	Vascular mode of action of kinin B <sub>1</sub> receptors and development of a cellular model for the investigation of these receptors. <i>British Journal of Pharmacology</i> , 1993, 109, 1254-1262.	2.7	50
157	Synergism between the contractile effect of epidermal growth factor and that of des-Arg <sup>9</sup> -bradykinin or of $\pm$ -thrombin in rabbit aortic rings. <i>British Journal of Pharmacology</i> , 1992, 105, 959-967.	2.7	40
158	Comparison of two classes of non-peptide drugs as antagonists of neutrophil receptors for f-Met-Leu-Phe. <i>Biochemical Pharmacology</i> , 1992, 43, 553-560.	2.0	9
159	Effects of experimental conditions on the production of interleukin-1 $\pm$ and -1 <sup>2</sup> by human endothelial cells cultured in vitro. <i>International Journal of Immunopharmacology</i> , 1992, 14, 525-534.	1.1	17
160	Synthesis and pharmacological evaluation of amide derivatives of non-steroidal anti-inflammatory drugs. <i>Inflammopharmacology</i> , 1992, 1, 201-212.	1.9	7
161	Human interleukin-1 induces a rapid relaxation of the rabbit isolated mesenteric artery. <i>British Journal of Pharmacology</i> , 1991, 103, 1367-1372.	2.7	34
162	Pulse exposure to protein synthesis inhibitors enhances vascular responses to des-Arg <sup>9</sup> -bradykinin: possible role of interleukin-1. <i>British Journal of Pharmacology</i> , 1991, 103, 1057-1066.	2.7	85

#	ARTICLE	IF	CITATIONS
163	Relaxant Effect of Chemotactic Peptides on Rabbit Vascular Strips: Evidence for Nitric Oxide Release from a Nonendothelial Source. <i>Journal of Vascular Research</i> , 1991, 28, 452-463.	0.6	1
164	The interaction of 3,5-pyrazolidinedione drugs with receptors for f-Met-Leu-Phe on human neutrophil leukocytes: a study of the structure-activity relationship. <i>Canadian Journal of Physiology and Pharmacology</i> , 1991, 69, 419-425.	0.7	15
165	Pharmacological modulation of interleukin 1 production by cultured endothelial cells from human umbilical veins. <i>Immunopharmacology</i> , 1990, 19, 121-130.	2.0	21
166	Contractile effect of the chemotactic factors f-Met-Leu-Phe and C5a on the human isolated umbilical artery. Role of cyclooxygenase products and tissue macrophages.. <i>Circulation Research</i> , 1990, 67, 1059-1070.	2.0	27
167	Long-term culture and characterization of human limbal microvascular endothelial cells. <i>Experimental Eye Research</i> , 1990, 51, 645-650.	1.2	7
168	Bacitracin U.S.P. contains a factor that stimulates receptors for 5-hydroxytryptamine on rabbit aortic strips. <i>Life Sciences</i> , 1990, 47, PL103-PL108.	2.0	2
169	Pharmacological modulation of the up-regulated responses to des-Arg9-bradykinin in vivo and in vitro. <i>Immunopharmacology</i> , 1989, 17, 187-198.	2.0	51
170	Prostacyclin release induced by neurokinins in cultured human endothelial cells. <i>Canadian Journal of Physiology and Pharmacology</i> , 1989, 67, 159-162.	0.7	25
171	Studies on the effects of disease-modifying antirheumatic drugs on lipoxigenase product synthesis in human neutrophils in vitro. <i>International Journal of Immunopharmacology</i> , 1988, 10, 709-715.	1.1	1
172	Effect of glucocorticoids, monokines and growth factors on the spontaneously developing responses of the rabbit isolated aorta to des-Arg <sup>9</sup> -bradykinin. <i>British Journal of Pharmacology</i> , 1988, 93, 969-977.	2.7	111
173	Small fibronectin fragments induce endothelium-dependent vascular relaxations. <i>Canadian Journal of Physiology and Pharmacology</i> , 1988, 66, 745-748.	0.7	8
174	The ability of des-Arg9-bradykinin to relax rabbit isolated mesenteric arteries is acquired during in vitro incubation. <i>European Journal of Pharmacology</i> , 1987, 142, 141-144.	1.7	42
175	Studies on the induction of pharmacological responses to des-Arg <sup>9</sup> -bradykinin in vitro and in vivo. <i>British Journal of Pharmacology</i> , 1987, 92, 257-264.	2.7	143
176	Carboxypeptidase N (Kininase I) activity in blood and synovial fluid from patients with arthritis. <i>Life Sciences</i> , 1987, 41, 1225-1232.	2.0	17
177	Effects of low molecular weight fibrin degradation products 6A and 6D on rabbit aorta strips. <i>Agents and Actions</i> , 1987, 22, 43-49.	0.7	7
178	Effects of the anaphylatoxins on circulation. <i>Immunopharmacology</i> , 1987, 14, 67-84.	2.0	51
179	Mitogenic effect of bradykinin and of des-Arg9-bradykinin on cultured fibroblasts. <i>Life Sciences</i> , 1986, 39, 2351-2358.	2.0	43
180	Anaphylatoxin C5a fails to promote prostacyclin release in cultured endothelial cells from human umbilical veins. <i>Immunopharmacology</i> , 1986, 12, 135-143.	2.0	23

#	ARTICLE	IF	CITATIONS
181	Effects of the C5a anaphylatoxin and its relationship to cyclooxygenase metabolites in rabbit vascular strips. <i>British Journal of Pharmacology</i> , 1985, 84, 725-733.	2.7	30
182	Selective Induction of Cardiovascular Responses to des-Arg <sup>9</sup> -Bradykinin by Bacterial Endotoxin. <i>Pharmacology</i> , 1984, 29, 70-74.	0.9	35
183	Rapid assay of human plasma carboxypeptidase N by high-performance liquid chromatographic separation of hippuryl-lysine and its product. <i>Journal of Chromatography A</i> , 1983, 266, 173-177.	1.8	9
184	Pharmacology of kinins: Their relevance to tissue injury and inflammation. <i>General Pharmacology</i> , 1983, 14, 209-229.	0.7	253
185	Kininases and vascular responses to kinins. <i>European Journal of Pharmacology</i> , 1982, 78, 167-174.	1.7	24
186	Induction of B1-receptors for kinins in the rabbit by a bacterial lipopolysaccharide. <i>European Journal of Pharmacology</i> , 1981, 71, 105-115.	1.7	197
187	The degradation of bradykinin (BK) and of des-Arg <sup>9</sup> -BK in plasma. <i>Canadian Journal of Physiology and Pharmacology</i> , 1981, 59, 131-138.	0.7	37
188	Pharmacological characterization of the vascular permeability enhancing effects of kinins in the rabbit skin. <i>Canadian Journal of Physiology and Pharmacology</i> , 1981, 59, 921-926.	0.7	37
189	Kinin receptors in experimental inflammation. <i>Canadian Journal of Physiology and Pharmacology</i> , 1980, 58, 536-542.	0.7	88
190	Cardiovascular actions of kinins in the rabbit. <i>Canadian Journal of Physiology and Pharmacology</i> , 1979, 57, 78-91.	0.7	46
191	The rabbit mesenteric vein: a specific bioassay for substance P. <i>Canadian Journal of Physiology and Pharmacology</i> , 1978, 56, 603-609.	0.7	18
192	De novo formation of vascular receptors for bradykinin. <i>Canadian Journal of Physiology and Pharmacology</i> , 1978, 56, 674-677.	0.7	124